Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908744 | 0.94 | LMNA (0.55) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL1908729 | 0.86 | CKS1B (0.56) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL13890887 | 0.86 | LMNA (0.55) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL13449930 | 0.86 | LMNA (0.57) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL1913123 | 0.83 | CA12 (0.52) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL4233141 | 0.83 | ALDH1A1 (0.55) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL359214 | 0.82 | CA12 (0.55) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL12015977 | 0.82 | CA12 (0.55) | LMNAALDH1A1DRD2CA12CA1 | |
| SCHEMBL360521 | 0.82 | KDM4E (0.54) | ALDH1A1DRD2KDM4EGPR119DRD3 | |
| SCHEMBL2301058 | 0.81 | CKS1B (0.60) | LMNAALDH1A1DRD2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | LMNA 3993/4885ALDH1A1 166/4885DRD2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.